26 Comments
 

Coverage should be your main goal, and it’s competitive to place in coverage so come off prepared and genuine.

Placement formally starts like a month or two before but is pretty much done around 3 months prior to start date. I’d start having informal chats by January.

I’d suggest avoiding FIG for obvious pigeon-hole reasons, but it’s a strong group.

My rankings in terms of exits: FSG (based on history although last few exits haven’t been great), Healthcare, P&U, Industrials (absolute sweatshop but good deal experience), Tech, Consumer

 
Most Helpful

Echoing above but with a slight reorder and context:

--

Tier 1: Top Coverage

Sponsors: Small SA class (~3) but historically fantastic exits

Healthcare: Probably the most UMM/MF exits on a volume basis (ex. Carlyle, GA, KKR, TPG, THL, WCAS)

Tech: Long hours but solid UMM/MF exits, especially in recent years (ex. Vista, Apax, CVC, GTCR, MDP)

Industrials: Long hours but solid UMM/MF exits, especially in recent years (ex. BX, CD&R, Elliot, Charlesbank, BC Partners)

PU&I: Top group on the street + fantastic infra-PE exits. I know I'm going to get attacked, but unless you want to do climate-tech/infra PE (ex. KKR Infra, TPG Rise Climate, BX Infra) PU&I is not worth the effort during group placement

--

Tier 2: Rest of Coverage

Energy Transition (fka NatRes): Lost a bit of its luster in recent years. Also pigeon holes you pretty hard for exits

Consumer: Just is not as strong from a dealflow/exits perspective. Mostly MM/UMM exits

FIG: Strong but, as said above, super niche and limiting in terms of exits. Mostly MM exits

Communication & Media: Weak dealflow (exclusive sell-side for Verizon-Frontier though wtf). Mostly MM exits

--

Tier 3: Can still muster up an exit

REGAL: Niche, limited exits, limited dealflow

LevFinAt least you would have some hope for exits

M&A: See above. Basically no modeling though because it's done in coverage groups

--

Tier 4: Good Luck

Rest of Product: ECM/DCM, Restructuring, Global Finance Advisory, PCM, LATAM M&A

 

Spot on. Sponsors is a mess for group placement and hasn't even placed super well recently. PU&I/NatRes are strong but don't do well in generalist PE placement.

If I were OP, I would prioritize Healthcare, Tech, Industrials (in that order)

 

Pretty accurate, prospect has done his research (or works at the firm). Am in Tier 1 but have seen more decent M&A exits even during the ESG days so curious to see how that holds up in the future.

 

Would caveat that hours are notoriously long in healthcare, tech, and industrials. Solid dealflow, but lots of new MDs who have no problem cranking you on multiple live deals + pitches as they find their footing.

I think healthcare has turned the page a bit more in terms of turnover - the team has stabilized a bit recently besides Thompson leaving for Lazard. Tech hires have looked great on paper - 2 Goldman MDs, David King from BofA, Singhal from Citi, and Patterson from MS. Similar story from Industrials, who brought in 2 new MDs this week. 

Think it should be highlighted how sentiment around Barclays has been around lack of MD quality top to bottom, but I think PU&I, Tech, HC, Industrials, and Sponsors have largely managed to replenish their talent. Same can't be said about other groups, so if OP wants to exit with some solid deal experience, I would stick with those 5 groups to be safe.

 

Recent years M&A group exits: Carlyle, Vector, WCAS, Hill Path, BC Partners

Historic analyst  class size between 2-4, do the math on per capita placement considering Industrials/Healthcare/Tech all have ~10 or 10+ first years

 

No one at Barclays considers M&A to be remotely on par with the Sponsors/PU&I/HC/Tech/Industrials. Terrible advice given it is an execution/sales group that doesn’t touch any sort of model. Not sure where your exit stats are from or over what time frame, because they do not exit nearly as well as the top coverage groups listed above.

 

Would not call it a safe bet at all. Industrials is a bit more lenient on who they take (~10+ class size with the addition of Chemicals now), but Tech and Healthcare are notoriously picky about what school you were from; very target/high-semi-target heavy (Harvard, Stern, Penn, Cornell, etc.)

 

It's a fine group. I don't have any macro insight on where the group stands, but they seem to get a good amount of work. Barclays as a whole is decent in the realm of financing deals (as with alot of BBs). Will note that Barclays LevFin does not model - you will work alongside coverage heavily but they hold pen.

WLB rocks compared to those sweaty coverage groups though

 

It has historically been a very strong LevFin group on the street, however things have really soured in the past 18 months. Once the "new guard" really started to try and make their mark (starting with the ousting of the former global head of LevFin and promoting a European counterpart to run a US-centric business), many of the core MDs in LevFin left along with the FSG group (which is equally important to the success of the LevFin group).

Mid-levels got shuffled around on verticals they covered (some for 5+ years) because they basically had to turn the group on its head. Sounds like a mess, would avoid. 

 

Consequatur accusamus sint velit. Non odit optio voluptas ut aperiam voluptas. Iusto qui molestias quo cum voluptatum. Sunt quae doloribus hic earum minus fuga. At unde et architecto asperiores adipisci. Eveniet reiciendis dolor et labore nihil esse.

Earum velit deserunt neque culpa nisi cupiditate. Mollitia cum vel qui qui similique dolores. Aut quis provident voluptatem corrupti quo natus totam. Consequatur aut ut ad consequatur sit repellat. Eveniet et et autem tenetur.

Ut inventore architecto ea eligendi sit sit neque. Facilis voluptas ut deleniti expedita molestias. Unde error expedita exercitationem repudiandae.

Commodi et rerum adipisci similique. Fugit et consectetur dolorem. Ut nam optio sint necessitatibus repellat nihil laborum qui.

 
Funniest

Asperiores officia libero minima mollitia aut. Placeat aut magnam harum est maiores. Voluptate minus est et qui.

Recusandae sunt exercitationem sit quisquam nostrum. Molestiae qui consectetur itaque nihil voluptas qui. Recusandae tempora rerum rerum laborum. Dolorem quia rerum non voluptatem ut qui aut cum.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 01 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (75) $151
  • Intern/Summer Analyst (67) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
DrApeman's picture
DrApeman
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
GameTheory's picture
GameTheory
98.9
8
dosk17's picture
dosk17
98.9
9
CompBanker's picture
CompBanker
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”